These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32814642)

  • 1. Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer.
    Aviki EM; Lavery JA; Roche KL; Cowan R; Dessources K; Basaran D; Green AK; Aghajanian CA; O'Cearbhaill R; Jewell EL; Leitao MM; Gardner GJ; Abu-Rustum NR; Sabbatini P; Bach PB
    Gynecol Oncol; 2020 Nov; 159(2):418-425. PubMed ID: 32814642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of National Cancer Institute Comprehensive Cancer Centers on ovarian cancer treatment and survival.
    Bristow RE; Chang J; Ziogas A; Campos B; Chavez LR; Anton-Culver H
    J Am Coll Surg; 2015 May; 220(5):940-50. PubMed ID: 25840536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surgical outcomes and national comprehensive cancer network compliance in advanced ovarian cancer surgery in a low volume military treatment facility.
    Phippen NT; Barnett JC; Lowery WJ; Miller CR; Leath CA
    Gynecol Oncol; 2013 Oct; 131(1):158-62. PubMed ID: 23872110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observed-to-expected ratio for adherence to treatment guidelines as a quality of care indicator for ovarian cancer.
    Galvan-Turner VB; Chang J; Ziogas A; Bristow RE
    Gynecol Oncol; 2015 Dec; 139(3):495-9. PubMed ID: 26387962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
    Chambers LM; Kuznicki M; Yao M; Chichura A; Gruner M; Reizes O; Debernardo R; Rose PG; Michener C; Vargas R
    Gynecol Oncol; 2020 Dec; 159(3):699-705. PubMed ID: 32950250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sociodemographic disparities in advanced ovarian cancer survival and adherence to treatment guidelines.
    Bristow RE; Chang J; Ziogas A; Campos B; Chavez LR; Anton-Culver H
    Obstet Gynecol; 2015 Apr; 125(4):833-842. PubMed ID: 25751200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in the receipt of guideline care and survival for women with ovarian cancer: A population-based study.
    Warren JL; Harlan LC; Trimble EL; Stevens J; Grimes M; Cronin KA
    Gynecol Oncol; 2017 Jun; 145(3):486-492. PubMed ID: 28372872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center.
    Erickson BK; Martin JY; Shah MM; Straughn JM; Leath CA
    Gynecol Oncol; 2014 May; 133(2):142-6. PubMed ID: 24517876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Risk-Adjusted Model for Ovarian Cancer Care and Disparities in Access to High-Performing Hospitals.
    Bristow RE; Chang J; Villanueva C; Ziogas A; Vieira VM
    Obstet Gynecol; 2020 Feb; 135(2):328-339. PubMed ID: 31923082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implementation of National Guidelines increased survival in advanced ovarian cancer - A population-based nationwide SweGCG study.
    Dahm-Kähler P; Holmberg E; Holtenman M; Rådestad AF; Borgfeldt C; Hjerpe E; Marcickiewicz J; Bjurberg M; Tholander B; Hellman K; Kjølhede P; Högberg T; Rosenberg P; Åvall-Lundqvist E; Stålberg K
    Gynecol Oncol; 2021 Apr; 161(1):244-250. PubMed ID: 33581846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of surgical volume on short-term outcomes of cytoreductive surgery for advanced-stage ovarian cancer: A population-based study from the Dutch Gynecological Oncology Audit.
    Algera MD; van Driel WJ; Slangen BFM; Wouters MWJM; Kruitwagen RFPM;
    Gynecol Oncol; 2024 Jul; 186():144-153. PubMed ID: 38688188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-term survival analysis of a risk-adjusted model for ovarian cancer care.
    Hari A; Chang J; Villanueva C; Ziogas A; Vieira V; Bristow RE
    Gynecol Oncol; 2024 May; 184():123-131. PubMed ID: 38309029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer.
    Liu YL; Zhou QC; Iasonos A; Filippova OT; Chi DS; Zivanovic O; Sonoda Y; Gardner G; Broach V; OCearbhaill R; Konner JA; Aghajanian CA; Long K; Tew W
    Int J Gynecol Cancer; 2020 Oct; 30(10):1554-1561. PubMed ID: 32522770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
    Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
    Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased disease-free and relative survival in advanced ovarian cancer after centralized primary treatment.
    Palmqvist C; Staf C; Mateoiu C; Johansson M; Albertsson P; Dahm-Kähler P
    Gynecol Oncol; 2020 Nov; 159(2):409-417. PubMed ID: 32943206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncologic outcomes after splenectomy during initial cytoreductive surgery in advanced epithelial ovarian cancer: a nationwide population-based cohort study.
    Said SA; van der Aa MA; Veldmate G; de Hullu JA; van Altena AM
    Acta Obstet Gynecol Scand; 2022 Jan; 101(1):56-67. PubMed ID: 34719790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
    Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
    J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to European ovarian cancer guidelines and impact on survival: a French multicenter study (FRANCOGYN).
    Jochum F; De Rozario T; Lecointre L; Faller E; Boisrame T; Dabi Y; Lavoué V; Coutant C; Touboul C; Bolze PA; Bricou A; Canlorbe G; Collinet P; Huchon C; Bendifallah S; Ouldamer L; Mezzadri M; Querleu D; Akladios C
    Int J Gynecol Cancer; 2021 Nov; 31(11):1443-1452. PubMed ID: 34607855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of race, socioeconomic status, and the health care system on the treatment of advanced-stage ovarian cancer in California.
    Long B; Chang J; Ziogas A; Tewari KS; Anton-Culver H; Bristow RE
    Am J Obstet Gynecol; 2015 Apr; 212(4):468.e1-9. PubMed ID: 25448522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.